{"name":"Lonza Group","slug":"lonza","ticker":"LONN.SW","exchange":"SIX","domain":"lonza.com","description":"Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.","hq":"Basel, Switzerland","founded":1996,"employees":"20000","ceo":"Wolfgang Wienand","sector":"CDMO / Life Sciences","stockPrice":474.2,"stockChange":-3.9,"stockChangePercent":-0.82,"marketCap":"$42.3B","metrics":{"revenue":8339824208.623718,"revenueGrowth":0,"grossMargin":36,"rdSpend":0,"netIncome":1160756458.2,"cash":918134096.1999999,"dividendYield":1.05,"peRatio":36.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lupin's generic version of Lonza's API patent cliff ($100.0M at risk)","drug":"Lupin's generic version of Lonza's API","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Lonza Group Reports Strong Q4 2023 Results","summary":"Lonza Group reported strong Q4 2023 results, with revenue growth and increased profitability.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Lonza Group Partners with Biogen to Develop New Biologics","summary":"Lonza Group partnered with Biogen to develop new biologics, expanding their capabilities in the biotech industry.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"regulatory","headline":"Lonza Group Receives FDA Approval for New API Manufacturing Facility","summary":"Lonza Group received FDA approval for their new API manufacturing facility, expanding their capacity and capabilities.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOcEszejE0MHFfRXZKcDZqd2lLaDNpdEN2SXhhTURiUHIwZW5xci1RTS16S0E0YlN4cVppWXJwaGMtbE9jYU1pN1dNbGVFTG5OMUlPN2pibWNwWExhRE5NQWhzMktpNnMyOUxySEJEUnR5QWJOdHZtT3h6QmdBQVY0OXVQT0NXM3ZoWTlEWHF3RE85TkFzVWJCUDR1UQ?oc=5","date":"2025-09-25","type":"pipeline","source":"Yahoo Finance","summary":"Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC - Yahoo Finance","headline":"Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFA1V1AyQzNRTkZiOFZNSUs2TmNVQlFGd0ZaWnRBemNuSWZDZUVUQUEzcTExY2tnQ0tZZmtVWkhQZmpESU00YXJfcnQ5Wl8wWlNVd2dpRQ?oc=5","date":"2025-07-01","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Xtrackers MSCI Innovation UCITS ETF 1C USD Acc (XNNS.L) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Xtrackers MSCI Innovation UCITS ETF 1C USD Acc (XNNS.L) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOVXpqQnM1aVFzNmpnWWZUcHhPWDB4Q1I0S0dxNUtEYTczb0dndVNGcFN0YkpMTllGdy1fek9EZnhUNVFYNnFSUDFJdFoyUHVsUnJabERBU2dYRjFoNkFkR3hFZnlkQTRYZ2lBNG5HdGFwaGhIMzlMN21DbUZvNWhhY05rc0ZuMDlLUXUxczc1ZjZ2TTlHMFdwVnludEU?oc=5","date":"2024-11-18","type":"pipeline","source":"Quiver Quantitative","summary":"ROBO Global Healthcare Technology and Innovation ETF Holdings - Quiver Quantitative","headline":"ROBO Global Healthcare Technology and Innovation ETF Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1GNFJuMnhoR2tnWUs0V2lzcW5KUUp5UjRPb0NrNHlBa2RDWTJIZkVhOENZbUFaSWszdl83NXhnamFVUWs1VVd2UV9jNGtjSkc3VTlNLVNn?oc=5","date":"2017-05-24","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Bachem Holding AG (BANB.SW) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Bachem Holding AG (BANB.SW) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Lupin's generic version of Lonza's API","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Catalent","Thermo Fisher Scientific","Sartorius AG"],"therapeuticFocus":["Oncology","Vaccines"],"financials":{"source":"yahoo_finance","revenue":8339824453.8,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":8339824453.8},{"period":"2024-12-31","value":6997739704},{"period":"2023-12-31","value":8577338976.599999},{"period":"2022-12-31","value":7946520835.4}],"grossProfit":2948500178.2,"grossProfitHistory":[{"period":"2025-12-31","value":2948500178.2},{"period":"2024-12-31","value":2289588921.4},{"period":"2023-12-31","value":2487517690.4},{"period":"2022-12-31","value":3113227992.4}],"rdSpend":143019497.6,"rdSpendHistory":[{"period":"2025-12-31","value":143019497.6},{"period":"2024-12-31","value":130249899.6},{"period":"2023-12-31","value":134080779},{"period":"2022-12-31","value":121311181}],"sgaSpend":976874247,"operatingIncome":1734111408.3999999,"operatingIncomeHistory":[{"period":"2025-12-31","value":1734111408.3999999},{"period":"2024-12-31","value":1122447664.2},{"period":"2023-12-31","value":1114785905.4},{"period":"2022-12-31","value":1732834448.6}],"netIncome":-351163945,"netIncomeHistory":[{"period":"2025-12-31","value":-351163945},{"period":"2024-12-31","value":812146432.8},{"period":"2023-12-31","value":835131709.1999999},{"period":"2022-12-31","value":1551506157}],"eps":8.92,"epsHistory":[{"period":"2024-12-31","value":8.92},{"period":"2023-12-31","value":8.88},{"period":"2022-12-31","value":16.34},{"period":"2021-12-31","value":39.52}],"cash":918134096.1999999,"cashHistory":[{"period":"2025-12-31","value":918134096.1999999},{"period":"2024-12-31","value":1418702337.8},{"period":"2023-12-31","value":1874576986.3999999},{"period":"2022-12-31","value":1709849172.2}],"totalAssets":22866519138.6,"totalLiabilities":12694257371.8,"totalDebt":5797397492,"equity":10104582897.4,"operatingCashflow":1476165528.8,"operatingCashflowHistory":[{"period":"2025-12-31","value":1476165528.8},{"period":"2024-12-31","value":1626846785.2},{"period":"2023-12-31","value":1772420202.3999999},{"period":"2022-12-31","value":1302498996}],"capex":-1753265805.3999999,"capexHistory":[{"period":"2025-12-31","value":-1753265805.3999999},{"period":"2024-12-31","value":-1809452036.6},{"period":"2023-12-31","value":-2147846383.6},{"period":"2022-12-31","value":-2390468745.6}],"freeCashflow":-277100276.6,"dividendsPaid":-360102663.59999996,"buybacks":-661465176.4,"employees":20000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":474.2,"previousClose":478.1,"fiftyTwoWeekHigh":594.8,"fiftyTwoWeekLow":454.6,"fiftyTwoWeekRange":"454.6 - 594.8","fiftyDayAverage":497.18,"twoHundredDayAverage":532.17,"beta":0.82,"enterpriseValue":47417516526.0546,"forwardPE":21.7,"priceToBook":4.19,"priceToSales":5.07,"enterpriseToRevenue":5.69,"enterpriseToEbitda":17.38,"pegRatio":1.43,"ebitda":2728863010.8745728,"ebitdaMargin":32.7,"freeCashflow":-2297091070.4406786,"operatingCashflow":1476165528.8,"totalDebt":5974894985.925427,"debtToEquity":58.7,"currentRatio":1.89,"returnOnAssets":4.6,"returnOnEquity":10.5,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":23,"targetMeanPrice":669.61,"targetHighPrice":815,"targetLowPrice":550,"dividendRate":5,"payoutRatio":0.31,"fiveYearAvgDividendYield":0.66,"exDividendDate":1778544000,"insiderHeldPercent":0.1,"institutionHeldPercent":59.7,"sharesOutstanding":69844229,"floatShares":69810005,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":12.99,"epsForward":21.81,"revenuePerShare":93.27,"bookValue":113.3,"officers":[{"age":53,"name":"Dr. Wolfgang  Wienand Ph.D.","title":"Chief Executive Officer"},{"age":null,"name":"Mr. Philippe  Deecke","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Jason  Berndt","title":"Executive VP & Head of Group Operations"},{"age":null,"name":"Mr. Daniel  Buchta","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Andreas  Bohrer","title":"Chief Legal & Corporate Affairs Officer"},{"age":null,"name":"Ms. Kim  Harrelson","title":"Head of Ethics & Compliance, ERM and Corporate Responsibility"},{"age":null,"name":"Ms. Victoria  Morgan","title":"Head of External Communications"},{"age":null,"name":"Ms. Jennifer  Clancy","title":"Senior Director of Global Marketing"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.lonza.com","phone":"41 61 316 81 11"}}